WST — West Pharmaceutical Services Share Price
Last trade - 00:00- $27.82bn
- $27.17bn
- $2.95bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 47.33 | ||
| PEG Ratio (f) | 145.37 | ||
| EPS Growth (f) | 0.33% | ||
| Dividend Yield (f) | 0.26% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.66 | ||
| Price to Tang. Book | 10.09 | ||
| Price to Free Cashflow | 67.11 | ||
| Price to Sales | 9.43 | ||
| EV to EBITDA | 32.82 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 21.53% | ||
| Return on Equity | 21.32% | ||
| Operating Margin | 23.05% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,839.9 | 2,146.9 | 2,831.6 | 2,886.9 | 2,949.8 | 3,011.18 | 3,284.61 | 11.43% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +15.83 | +43.83 | +86.1 | -4.02 | -2.88 | -6.55 | +18.79 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates through two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers packaging, containment solutions, and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
Directors
- Patrick Zenner NEC (74)
- Eric Green PRE (51)
- Bernard Birkett CFO (52)
- David Montecalvo COO (55)
- Annette Favorite CHO (56)
- Silji Abraham SVP (49)
- Kimberly Mackay SVP (55)
- Chad Winters CAO (42)
- Quintin Lai VPR (54)
- Molly Joseph DRC (47)
- Mark Buthman IND (60)
- William Feehery IND (51)
- Robert Friel IND (65)
- Thomas Hofmann IND (69)
- Deborah Keller Tanner IND (58)
- Myla Lai-Goldman IND (63)
- Douglas Michels IND (64)
- Paolo Pucci IND (60)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 27th, 1923
- Public Since
- July 27th, 1923
- No. of Shareholders
- 574
- No. of Employees
- 10,600
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 73,205,367
- Address
- 530 Herman O. West Drive, EXTON, 19341
- Web
- https://www.westpharma.com/
- Phone
- +1 6105942900
- Auditors
- PricewaterhouseCoopers LLP
Latest News for WST
Upcoming Events for WST
Dividend For W2ST34.SA - 0.0282 BRL
Dividend For WST.N - 0.2000 USD
West Pharmaceutical Services Inc Annual Shareholders Meeting
Q1 2024 West Pharmaceutical Services Inc Earnings Release
Q1 2024 West Pharmaceutical Services Inc Earnings Call
West Pharmaceutical Services Inc Annual Shareholders Meeting
Q2 2024 West Pharmaceutical Services Inc Earnings Release
Similar to WST
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Agiliti
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
FAQ
As of Today at 19:24 UTC, shares in West Pharmaceutical Services are trading at $380.00. This share price information is delayed by 15 minutes.
Shares in West Pharmaceutical Services last closed at $380.00 and the price had moved by +3.62% over the past 365 days. In terms of relative price strength the West Pharmaceutical Services share price has underperformed the S&P500 Index by -16.32% over the past year.
The overall consensus recommendation for West Pharmaceutical Services is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The West Pharmaceutical Services dividend yield is 0.2% based on the trailing twelve month period.
Last year, West Pharmaceutical Services paid a total dividend of $0.77, and it currently has a trailing dividend yield of 0.2%.Looking ahead, shares in West Pharmaceutical Services are due to go ex-dividend on 2024-04-23 and the next dividend pay date is 2024-05-01.
West Pharmaceutical Services are due to go ex-dividend on 2024-04-23 and the next dividend pay date is 2024-05-01. The historic dividend yield on West Pharmaceutical Services shares is currently 0.2%.
To buy shares in West Pharmaceutical Services you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $380.00, shares in West Pharmaceutical Services had a market capitalisation of $27.82bn.
Here are the trading details for West Pharmaceutical Services:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: WST
Based on an overall assessment of its quality, value and momentum West Pharmaceutical Services is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in West Pharmaceutical Services is $400.43. That is 5.38% above the last closing price of $380.00.
Analysts covering West Pharmaceutical Services currently have a consensus Earnings Per Share (EPS) forecast of $7.62 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like West Pharmaceutical Services. Over the past six months, its share price has underperformed the S&P500 Index by -15.76%.
As of the last closing price of $380.00, shares in West Pharmaceutical Services were trading +2.36% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The West Pharmaceutical Services PE ratio based on its reported earnings over the past 12 months is 47.33. The shares last closed at $380.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
West Pharmaceutical Services' management team is headed by:
- Patrick Zenner - NEC
- Eric Green - PRE
- Bernard Birkett - CFO
- David Montecalvo - COO
- Annette Favorite - CHO
- Silji Abraham - SVP
- Kimberly Mackay - SVP
- Chad Winters - CAO
- Quintin Lai - VPR
- Molly Joseph - DRC
- Mark Buthman - IND
- William Feehery - IND
- Robert Friel - IND
- Thomas Hofmann - IND
- Deborah Keller Tanner - IND
- Myla Lai-Goldman - IND
- Douglas Michels - IND
- Paolo Pucci - IND